Market Segmentation
- Breast Cancer Drugs Therapy Outlook (Revenue, USD Million, 2018 - 2030)
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Breast Cancer Drugs Cancer Type Outlook (Revenue, USD Million, 2018 - 2030)
- Breast Cancer Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Breast Cancer Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- North America Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- North America Breast Cancer Drugs Market, By Cancer Type
- North America Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- U.S.
- U.S. Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- U.S. Breast Cancer Drugs Market, By Cancer Type
- U.S. Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Canada
- Canada Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Canada Breast Cancer Drugs Market, By Cancer Type
- Canada Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Europe
- Europe Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Europe Breast Cancer Drugs Market, By Cancer Type
- Europe Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- UK
- UK Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- UK Breast Cancer Drugs Market, By Cancer Type
- UK Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Germany
- Germany Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Germany Breast Cancer Drugs Market, By Cancer Type
- Germany Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Frane
- Frane Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Frane Breast Cancer Drugs Market, By Cancer Type
- Frane Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Italy
- Italy Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Italy Breast Cancer Drugs Market, By Cancer Type
- Italy Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Spain
- Spain Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Spain Breast Cancer Drugs Market, By Cancer Type
- Spain Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Denmark
- Denmark Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Denmark Breast Cancer Drugs Market, By Cancer Type
- Denmark Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Sweden
- Sweden Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Sweden Breast Cancer Drugs Market, By Cancer Type
- Sweden Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Norway
- Norway Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Norway Breast Cancer Drugs Market, By Cancer Type
- Norway Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Asia Pacific
- Asia Pacific Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Asia Pacific Breast Cancer Drugs Market, By Cancer Type
- Asia Pacific Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Japan
- Japan Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Japan Breast Cancer Drugs Market, By Cancer Type
- Japan Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- China
- China Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Chinaa Breast Cancer Drugs Market, By Cancer Type
- China Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- India
- India Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- India Breast Cancer Drugs Market, By Cancer Type
- India Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Australia
- Australia Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Australia Breast Cancer Drugs Market, By Cancer Type
- Australia Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Thailand
- Thailand Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Thailanda Breast Cancer Drugs Market, By Cancer Type
- Thailand Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Latin America
- Latin America Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Latin America Breast Cancer Drugs Market, By Cancer Type
- Latin America Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Brazil
- Brazil Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Brazil Breast Cancer Drugs Market, By Cancer Type
- Brazil Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Mexico
- Mexico Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Mexico Breast Cancer Drugs Market, By Cancer Type
- Mexico Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Argentina
- Argentina Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Argentina Breast Cancer Drugs Market, By Cancer Type
- Argentina Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Middle East & Africa
- Middle East & Africa Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Middle East & Africa Breast Cancer Drugs Market, By Cancer Type
- Middle East & Africa Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- South Africa
- South Africa Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- South Africa Breast Cancer Drugs Market, By Cancer Type
- South Africa Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Saudi Arabia
- Saudi Arabia Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Saudi Arabia Breast Cancer Drugs Market, By Cancer Type
- Saudi Arabia Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- UAE
- UAE Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- UAE Breast Cancer Drugs Market, By Cancer Type
- UAE Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Kuwait
- Kuwait Breast Cancer Drugs Market, By Therapy
- Targeted Therapy
- Abemaciclib
- Ado-Trastuzumab Emtansine
- Everolimus
- Trastuzumab
- Ribociclib
- Palbociclib
- Pertuzumab
- Olaparib
- Others
- Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Down regulators (ERDs)
- Chemotherapy
- Immunotherapy
- Kuwait Breast Cancer Drugs Market, By Cancer Type
- Kuwait Breast Cancer Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breast Cancer Drugs Market Dynamics
Driver: Rising Incidence Rate of Breast Cancer Globally
The rise in incidence of breast cancer worldwide is expected to boost the market growth. Breast cancer is one of the most common cancers among women population and the second most prevalent cancer among others. The risk of cancer is considered at aging. With the increasing age, the immune system is affected. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed with breast cancer and only about 10% to 15% of breast cancer cases occur in women younger than 45. Based on the American Cancer Society, in 2020, 279,100 new cases of breast cancer were estimated to be diagnosed and around 42,690 deaths were expected to occur in the U.S. In addition, Breastcancer.org reported that as of January 2020, there were more than 3.5 million women suffering from breast cancer in the U.S.
Driver: High Investments in Research & Development (R&D) Activities
The rising number of research & development activities and growing spending on R&D activities is expected to fuel market growth. Rise in number of breast cancer cases among the women population is anticipated to drive market growth. According to the representation below, R&D spending of Sanofi; Celgene Corporation; AbbVie, Inc.; Pfizer, Inc.; GlaxoSmithKline plc; Merck & Co., Inc.; and Johnson & Johnson Services, Inc. has increased exponentially, whereas a steep decline was observed for Bristol-Myers Squibb Company; AstraZeneca; Novartis; and F. Hoffmann-La Roche Ltd. The statistics represent the overall R&D investments made in the financial year
Restraint: Patent Expiration to Hamper Market Growth
The loss of uniqueness of one or more important products is projected to have a negative impact on a company’s performance, which forces companies to look for new revenue stream. Furthermore, a shift in government focus to improving access and growing number of companies being subjected to price scrutiny are some of the factors expected to further reduce drug prices.
What Does This Report Include?
This section will provide insights into the contents included in this breast cancer drugs market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.
Breast cancer drugs market qualitative analysis
Breast cancer drugs market quantitative analysis
-
Market size, estimates, and forecast from 2018 to 2030
-
Market estimates and forecast for product segments up to 2030
-
Regional market size and forecast for product segments up to 2030
-
Market estimates and forecast for application segments up to 2030
-
Regional market size and forecast for application segments up to 2030
-
Company financial performance